The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Accelerating biologics: From final DNA to Phase I in under 9 months
On-demand webinar
Originally presented at BIO International 2025, this webinar explores how our novel Path to IND platform helps biotech companies move from DNA to first-in-human Phase I clinical trials in as little as nine months.* With integrated drug substance, drug product, clinical packaging and labeling, and regulatory and quality assurance support, our platform delivers unmatched speed, helping you reach key milestones quicker than ever before.
Gain insights into the advantages of leveraging artificial intelligence/machine learning, transposase technology, and the world-class CHO-K1 cell line—and see why drug developers choose Thermo Fisher Scientific as their CDMO and CRO partner. While the webinar focuses on early-stage acceleration, we also support downstream scale-up for clinical and commercial manufacturing, ensuring a seamless transition as your program advances.
Key learnings include:
- The evolution of our biologics capabilities
- An overview of our novel Path to IND program
- The value of strategic client collaboration
Terms and Conditions: Titer levels provided are estimates based on third-party results and may vary depending on molecule type or other factors. Timelines from DNA to drug product and the start of clinical trials for all Path to IND for biologics options may vary depending on molecule type or other factors and are estimates to be finalized once third-party cell line development dates are available and confirmed. The 9-month timeline may incur additional risk.